• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)

    10/21/22 4:31:00 PM ET
    $ZY
    Industrial Specialties
    Industrials
    Get the next $ZY alert in real time by email
    SC 13G/A 1 d273702dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Zymergen Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    98985X100

    (CUSIP Number)

    October 19, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 98985X100    Schedule 13G    Page 1 of 8

     

     

      1    

      Names of Reporting Persons

     

      SB Investment Advisers (UK) Limited

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      England and Wales

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      0

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12  

      Type of Reporting Person

     

      CO


    CUSIP No. 98985X100    Schedule 13G    Page 2 of 8

     

     

      1    

      Names of Reporting Persons

     

      SoftBank Vision Fund (AIV M1) L.P.

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      0

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12  

      Type of Reporting Person

     

      PN


    CUSIP No. 98985X100    Schedule 13G    Page 3 of 8

     

     

      1    

      Names of Reporting Persons

     

      SVF Endurance (Cayman) Limited

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      0

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12  

      Type of Reporting Person

     

      CO


    CUSIP No. 98985X100    Schedule 13G    Page 4 of 8

     

     

      1    

      Names of Reporting Persons

     

      SVF Excalibur (Cayman) Limited

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      0

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      0.0%

    12  

      Type of Reporting Person

     

      CO


    CUSIP No. 98985X100    Schedule 13G    Page 5 of 8

     

    ITEM 1.

    (a) Name of Issuer:

    Zymergen Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    5959 Horton Street, Suite 700, Emeryville, California 94608

     

    ITEM 2.

    (a) Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    SB Investment Advisers (UK) Limited (“SBIA UK”)

    SoftBank Vision Fund (AIV M1) L.P. (“AIV M1”)

    SVF Endurance (Cayman) Limited

    SVF Excalibur (Cayman) Limited

     

      (b)

    Address or Principal Business Office:

    The address for SBIA UK is 69 Grosvenor Street, London W1K 3JP, United Kingdom. The address for AIV M1 is 251 Little Falls Drive, Wilmington, Delaware 19808. The address for each of SVF Excalibur (Cayman) Limited and SVF Endurance (Cayman) Limited is c/o Walkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.

     

      (c)

    Citizenship of each Reporting Person is:

    SBIA UK is organized under the laws of England and Wales. AIV M1 is organized under the laws of the State of Delaware. Each of SVF Excalibur (Cayman) Limited and SVF Endurance (Cayman) Limited is organized under the laws of the Cayman Islands.

     

      (d)

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”).

     

      (e)

    CUSIP Number:

    98985X100

     

    ITEM 3.

    Not applicable.


    CUSIP No. 98985X100    Schedule 13G    Page 6 of 8

     

    ITEM 4.

    Ownership.

    (a-c) This amendment to Schedule 13G is being filed to report that, as of the date hereof, the Reporting Persons do not beneficially own any shares of Common Stock.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. 98985X100    Schedule 13G    Page 7 of 8

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: October 21, 2022

     

    SB Investment Advisers (UK) Limited
    By:  

    /s/ Amanda Sanchez-Barry

    Name:   Amanda Sanchez- Barry
    Title:   General Counsel
    SoftBank Vision Fund (AIV M1) L.P.
    By:   SB Investment Advisers (UK) Limited, its manager
    By:  

    /s/ Amanda Sanchez-Barry

    Name:   Amanda Sanchez- Barry
    Title:   General Counsel
    SVF Endurance (Cayman) Limited
    By:  

    /s/ Jonathan Duckles

    Name:   Jonathan Duckles
    Title:   Director
    SVF Excalibur (Cayman) Limited
    By:  

    /s/ Jonathan Duckles

    Name:   Jonathan Duckles
    Title:   Director


    CUSIP No. 98985X100    Schedule 13G    Page 8 of 8

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $ZY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZY

    DatePrice TargetRatingAnalyst
    3/2/2022Market Perform
    Cowen
    1/12/2022$6.50Reduce → Hold
    HSBC Securities
    10/15/2021Market Perform
    Cowen
    9/27/2021$12.00Neutral → Underweight
    JP Morgan
    8/31/2021$56.00 → $13.00Buy → Neutral
    UBS
    8/4/2021$43.00 → $7.00Buy → Underperform
    BofA Securities
    8/4/2021Outperform → Market Perform
    Cowen & Co.
    8/4/2021$55.00 → $12.00Buy → Neutral
    Goldman Sachs
    More analyst ratings

    $ZY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks Completes Acquisition of Zymergen

    BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, and Zymergen (NASDAQ:ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome t

    10/19/22 9:08:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

    EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform. Octant has now more than doubled its initial investment through the purchase of an additional six RAC units, vastly increasing the system's throughput, capabilities, and ability to run complex workflows. "We've been extremely pleased with the performance of our current RAC System and are l

    7/14/22 4:56:39 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/21/22 4:30:20 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:17:59 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:15:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    3/2/22 8:44:04 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Zymergen from Reduce to Hold and set a new price target of $6.50

    1/12/22 7:08:41 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    10/15/21 7:34:23 AM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    SEC Filings

    View All

    SEC Form 15-12G filed by Zymergen Inc.

    15-12G - Zymergen Inc. (0001645842) (Filer)

    10/31/22 4:47:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form EFFECT filed by Zymergen Inc.

    EFFECT - Zymergen Inc. (0001645842) (Filer)

    10/26/22 12:15:12 AM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form POS AM filed by Zymergen Inc.

    POS AM - Zymergen Inc. (0001645842) (Filer)

    10/19/22 12:36:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)

    SC 13G/A - Zymergen Inc. (0001645842) (Subject)

    10/21/22 4:31:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 3:22:50 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 9:36:54 AM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Financials

    Live finance-specific insights

    View All

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Reports Preliminary First Quarter 2022 Financial Results

    EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r

    5/12/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022

    EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest

    4/13/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials